-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Fhybtisr9z9nG06avdr7EJXfBfH2Ulmnm4IWaAP7Xfy4KFk9bgApX+g+H4N6emoX Auf+FFSX6DetrTM+7WjACg== 0000893220-09-000310.txt : 20090217 0000893220-09-000310.hdr.sgml : 20090216 20090217141435 ACCESSION NUMBER: 0000893220-09-000310 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090217 DATE AS OF CHANGE: 20090217 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: TARGACEPT INC CENTRAL INDEX KEY: 0001124105 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-82442 FILM NUMBER: 09610182 BUSINESS ADDRESS: STREET 1: 200 EAST FIRST STREET STREET 2: SUITE 300 CITY: WINSTON-SALEM STATE: NC ZIP: 27101 BUSINESS PHONE: 3364802100 MAIL ADDRESS: STREET 1: 200 EAST FIRST STREET STREET 2: SUITE 300 CITY: WINSTON-SALEM STATE: NC ZIP: 27101 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC CENTRAL INDEX KEY: 0001131399 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS BUSINESS PHONE: 011442080475000 MAIL ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS SC 13G/A 1 w72776sc13gza.htm FORM SC 13G/A sc13gza
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
TARGACEPT, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
87611R306
(CUSIP Number)
December 31, 2008
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
o Rule 13d-1(c)
þ Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
This Amendment No. 1 amends and supplements the Statement on Schedule 13G electronically filed with the Securities and Exchange Commission (the “Commission”) on August 01, 2007 with respect of the ownership of securities of Targacept, Inc. (the “Initial Statement”).
The undersigned hereby amends and supplements Items 4 and 6 of Initial Statement with the following information (capitalized terms used herein without definition shall have the same meaning as set forth in the Initial Statement).
 
 

 

 

                     
CUSIP No.
  
87611R306 
  

 

           
1   NAMES OF REPORTING PERSONS . I.R.S. Identification Nos. of above persons (entities only)
GlaxoSmithKline plc
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o
  (b)   o
     
3   SEC USE ONLY
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  England and Wales
       
  5   SOLE VOTING POWER
     
NUMBER OF   1,424,176
       
SHARES 6   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   -0-
       
EACH 7   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   1,424,176
       
WITH 8   SHARED DISPOSITIVE POWER
     
    -0-
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  1,424,176
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  5.7%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  CO

2

 

CUSIP No. 87611R306
 
Item 1.
  (a)   Name of Issuer
 
     
 
 
  (b)   Address of Issuer’s Principal Executive Offices
 
     
 
Item 2.
  (a)   Name of Person Filing
 
     
 
 
  (b)   Address of Principal Business Office or, if none, Residence
 
     
 
 
  (c)   Citizenship
 
     
 
 
  (d)   Title of Class of Securities
 
     
 
 
  (e)   CUSIP Number
 
     
 
Item 3. Not applicable.

3

 

CUSIP No. 87611R306
 
Item 4. Ownership
The information in Items 1 and 5 through 11 on the cover pages (page 2) on Schedule 13G is hereby incorporated by reference.
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Shares held by following wholly-owned subsidiaries of Reporting Person:
Glaxo Group Limited                          1,096,932
SmithKline Beecham Corporation         327,244
Item 7.   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
Item 8. Identification and Classification of Members of the Group
Item 9. Notice of Dissolution of Group
Item 10. Certification
     By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

4

 

     After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
         
  GlaxoSmithKline plc
 		  
  By:   /s/ Victoria Whyte    
    Victoria Whyte   
    Deputy Company Secretary   
 

5

-----END PRIVACY-ENHANCED MESSAGE-----